High-dose methotrexate (HDMTX) remains a cornerstone of cancer therapy; nevertheless, failure to promptly recognise delayed methotrexate elimination (DME) and hesitancy to intervene can lead to avoidable toxicity, including acute kidney injury (AKI). This highly interactive 2-day meeting, taking place at Park Plaza Hotel London Waterloo, is designed to explore evolving approaches to the early detection and management of DME. The programme will integrate expert perspectives and shared clinical experience to support early identification and timely treatment decisions across the patient pathway. Accommodation on the 15-May and travel is included.

TOPICS COVERED

This masterclass will cover the end-to-end management of patients receiving HDMTX, with a focus on the prevention, identification, and treatment of DME, and consideration of associated complications, including AKI. 

Through a series of interactive sessions, participants will build confidence in monitoring patients across the full treatment pathway, interpreting clinical and pharmacokinetic data, and making timely, evidence-based decisions. 

An expert faculty will guide these sessions, sharing insights from clinical experience and facilitating peer-to-peer exchange, ensuring delegates leave with actionable approaches to optimise patient care and outcomes. Learning will be grounded in real-world practice, with case-based discussions designed to encourage reflection and practical application. 

Accommodation on the 15-May and travel is included.

WHO SHOULD ATTEND?

This meeting is organised and funded by SERB Pharmaceuticals and is intended for UK healthcare professionals involved in the use of HDMTX and the management of methotrexate-related toxicity resulting from DME.

SPEAKERS

• Prof Kate Cwynarski (Chair) | Professor of Haematological Oncology and Consultant Haematologist, University College London Hospital NHS Foundation Trust, London, UK 
• Prof Nicholas Selby | Royal Derby Hospital, Derby, UK 
• Rupal Evans | The Royal Marsden NHS Foundation, London, UK 
• Anish Tailor | University College London Hospitals NHS Foundation Trust, London, UK 
• Dr Katrina Ingley | University College London Hospitals NHS Foundation Trust, London, UK 
• Clare Geoghegan | University College London Hospitals NHS Foundation Trust, London, UK 
• Dr Jesper Heldrup | Childhood Cancer and Research Unit, University Children’s Hospital, Lund, Sweden 
• Vanessa McLelland | University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, UK 

For UK healthcare professionals only. This is a promotional meeting organised by SERB Pharmaceuticals. SERB products will be discussed during the event. Prescribing information and adverse event reporting can be found at the bottom of this page. 

Voraxaze® (glucarpidase) is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination.

The Prescribing Information and adverse event reporting for Voraxaze® can be found here.  

This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions. 

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to [email protected].

For more information, please contact: [email protected].
UK-VRX-2600056 | April 2026